Christopher Navara to Drug Design
This is a "connection" page, showing publications Christopher Navara has written about Drug Design.
Connection Strength
0.277
-
Navara CS. The spleen tyrosine kinase (Syk) in human disease, implications for design of tyrosine kinase inhibitor based therapy. Curr Pharm Des. 2004; 10(15):1739-44.
Score: 0.212
-
Uckun FM, Sudbeck EA, Mao C, Ghosh S, Liu XP, Vassilev AO, Navara CS, Narla RK. Structure-based design of novel anticancer agents. Curr Cancer Drug Targets. 2001 May; 1(1):59-71.
Score: 0.044
-
Jan ST, Mao C, Vassilev AO, Navara CS, Uckun FM. COBRA-1, a rationally-designed epoxy-THF containing compound with potent tubulin depolymerizing activity as a novel anticancer agent. Bioorg Med Chem Lett. 2000 Jun 05; 10(11):1193-7.
Score: 0.010
-
Uckun FM, Mao C, Vassilev AO, Navara CS, Narla RK, Jan ST. A rationally designed anticancer drug targeting a unique binding cavity of tubulin. Bioorg Med Chem Lett. 2000 May 15; 10(10):1015-8.
Score: 0.010